The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Featured:
During the 31st European Academy of Dermatology and Venereology (EADV) Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Paolo Gisondi, University Hospital of Verona, Verona, IT, and Jose-Manuel Carrascosa, Germans Trias i Pujol University Hospital, Barcelona, ES. We asked, Is a treatment goal of PASI100 appropriate in psoriasis management?
Carrascosa opens by discussing PASI100 as an optimal treatment goal but notes that this may not be achievable in all patients and may be a possible cause of disappointment when there is failure to meet it. Gisondi agrees and goes on to highlight the importance of distinguishing between an optimal treatment target and a realistic treatment target. He suggests that more achievable goals, such as PASI90, may be more appropriate. Gisondi and Carrascosa finish by discussing the importance of considering other outcomes, such as quality of life and disease modification, when assessing treatment goals.
Is a treatment goal of PASI100 appropriate in psoriasis management?